Cited by 28Gene expression and cancer classificationBreast Cancer Treatment StudiesBioinformatics and Genomic Networks

Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence

Open access
Wang, Yi Kan, Print, Cristin G, Crampin, Edmund J·2013·BMC Genomics

Abstract

BACKGROUND: Many studies have revealed correlations between breast tumour phenotypes, variations in gene expression, and patient survival outcomes. The molecular heterogeneity between breast tumours revealed by these studies has allowed prediction of prognosis and has underpinned stratified therapy, where groups of patients with particular tumour types receive specific treatments. The molecular tests used to predict prognosis and stratify treatment usually utilise fixed sets of genomic biomarkers, with the same biomarker sets being used to test all patients. In this paper we suggest that instead of fixed sets of genomic biomarkers, it may be more effective to use a stratified biomarker approach, where optimal biomarker sets are automatically chosen for particular patient groups, analogous to the choice of optimal treatments for groups of similar patients in stratified therapy. We illustrate the effectiveness of a biclustering approach to select optimal gene sets for determining the prognosis of specific strata of patients, based on potentially overlapping, non-discrete molecular characteristics of tumours. RESULTS: Biclustering identified tightly co-expressed gene sets in the tumours of restricted subgroups of breast cancer patients. The co-expressed genes in these biclusters were significantly enriched for particular biological annotations and gene regulatory modules associated with breast cancer biology. Tumours identified within the same bicluster were more likely to present with similar clinical features. Bicluster membership combined with clinical information could predict patient prognosis in conditional inference tree and ridge regression class prediction models. CONCLUSIONS: The increasing clinical use of genomic profiling demands identification of more effective methods to segregate patients into prognostic and treatment groups. We have shown that biclustering can be used to select optimal gene sets for determining the prognosis of specific strata of patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-2164-14-102

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Even when no sample classification is available, subpopulation-specific modules can be resolved, an approach that has been particularly successful in classifying different cancer subtypes to provide prognostic markers.

    “Even when no sample classification is available, subpopulation-specific modules can be resolved, an approach that has been particularly successful in classifying different cancer subtypes to provide prognostic markers [18–20].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

1 of the 55 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wang, Y. K., Print, C. G., & Crampin, E. J.
Affiliations
University of Auckland (NZ)
Corresponding author
Wang, Yi Kan
Venue
BMC Genomics
Published
2013
Volume
14
Issue
1
Pages
102
ISSN
1471-2164 (ISSN-L)
OpenAlex
W2171565067
Cited by
28
References
55
Citations by year
2024: 1 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 4 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 5 · 2013: 1
FWCI
1.94
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMC Genomics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Royal Society
  • Breast Cancer Research Trust
  • Royal Society Te Apārangi
  • Cancer Research Trust New Zealand
  • Marsden Fund
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
breast cancer, biclustering, disease recurrence prediction, prognostic factors, treatment stratification, gene co-expression, gene regulatory modules, patient stratification, conditional inference trees, ridge regression
MeSH terms
Adult, Aged, Aged, 80 and over, Algorithms, Breast Neoplasms, Humans, Middle Aged, Recurrence, Biomarkers, Tumor, Cluster Analysis, Disease-Free Survival, Computational Biology, Kaplan-Meier Estimate, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review